Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biological considerations for radioimmunotherapy.

R M Sharkey1, R D Blumenthal, H J Hansen

  • 1Center for Molecular Medicine and Immunology, University of Medicine and Dentistry of New Jersey, Newark 07103.

Cancer Research
|February 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study.

European journal of nuclear medicine and molecular imaging·2020
Same author

Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses.

Human vaccines & immunotherapeutics·2017
Same author

Anti-CEA antibody fragments labeled with [(18)F]AlF for PET imaging of CEA-expressing tumors.

Bioconjugate chemistry·2014

Researchers explored three methods to enhance radioimmunotherapy efficacy by reducing toxicity. Strategies include using antibody fragments, anti-antibodies, and cytokines to improve cancer treatment with radiolabeled antibodies.

Area of Science:

  • Oncology
  • Immunology
  • Radiochemistry

Background:

  • Radioimmunotherapy (RIT) faces limitations due to myelotoxicity and thrombocytopenia, primarily caused by prolonged radioantibody circulation.
  • Reducing the circulation time of radiolabeled antibodies is crucial for improving RIT's therapeutic index.

Purpose of the Study:

  • To investigate three novel methods for enhancing the therapeutic efficacy of antibody-targeted radionuclides.
  • To mitigate the dose-limiting toxicities associated with radioimmunotherapy.

Main Methods:

  • Utilized fractionated doses of 131I-labeled F(ab')2 fragments of murine monoclonal antibodies against human colonic cancer in an animal model.
  • Administered an anti-antibody (second antibody) to accelerate the clearance of radiolabeled anti-tumor antibodies from circulation.

Related Experiment Videos

  • Investigated the use of cytokines, such as interleukin-1, to stimulate white blood cell production and counteract myelotoxicity.

    • Main Results:

    • Fractionated F(ab')2 fragment administration showed similar tumoricidal activity to intact IgG but with significantly reduced normal tissue toxicity.
    • The use of a second antibody 48 hours post-administration of 131I-labeled anti-CEA antibody reduced toxicity twofold without compromising tumoricidal effects.
    • Cytokine administration, like interleukin-1, effectively increased circulating white blood cells, thereby reducing myelotoxicity.

    Conclusions:

    • Modifying biological factors limiting RIT can significantly improve cancer treatment outcomes.
    • Antibody fragments, anti-antibodies, and cytokine therapy represent promising strategies to enhance RIT safety and efficacy.